Weekly oral alendronate in mevalonate kinase deficiency

Donato Rigante, Luca Cantarini, Antonio Vitale, Flora Magnotti, Orso Maria Lucherini, Francesco Caso, Bruno Frediani, Mauro Galeazzi

Risultato della ricerca: Contributo in rivistaArticolo in rivista

15 Citazioni (Scopus)

Abstract

BACKGROUND: Mevalonate kinase deficiency (MKD) is caused by mutations in the MVK gene, encoding the second enzyme of mevalonate pathway, which results in subsequent shortage of downstream compounds, and starts in childhood with febrile attacks, skin, joint, and gastrointestinal symptoms, sometimes induced by vaccinations. METHODS: For a history of early-onset corticosteroid-induced reduction of bone mineral density in a 14-year-old boy with MKD, who also had presented three bone fractures, we administered weekly oral alendronate, a drug widely used in the management of osteoporosis and other high bone turnover diseases, which blocks mevalonate and halts the prenylation process. RESULTS: All of the patient's MKD clinical and laboratory abnormalities were resolved after starting alendronate treatment. CONCLUSIONS: This observation appears enigmatic, since alendronate should reinforce the metabolic block characterizing MKD, but is crucial because of the ultimate improvement shown by this patient. The anti-inflammatory properties of bisphosphonates are a new question for debate among physicians across various specialties, and requires further biochemical and clinical investigation.
Lingua originaleEnglish
pagine (da-a)196-N/A
RivistaOrphanet Journal of Rare Diseases
Volume2013
DOI
Stato di pubblicazionePubblicato - 2013

Keywords

  • Alendronate
  • Mevalonate kinase deficiency

Fingerprint

Entra nei temi di ricerca di 'Weekly oral alendronate in mevalonate kinase deficiency'. Insieme formano una fingerprint unica.

Cita questo